Alex is Epirium’s Chief Executive Officer, and a member of the board of directors. He previously served as Chief Operating Officer, Chief Operating/Chief Financial Officer, and Chief Financial Officer. Alex has broad operational and financial expertise, with more than 25 years of experience as a successful healthcare executive and institutional investor. Before joining Epirium, Alex was the founder, Chief Executive Officer, and portfolio manager of Reneo Capital Management LP, a successful healthcare investment fund. He previously served as Chief Financial Officer of Sophiris Bio, Inc. and Vice President of Finance for Amylin Pharmaceuticals.
Alex was a founder and senior advisor at Casdin Advisors, LLC, Chief Executive Officer and Portfolio Manager at Cooper Hill Partners, LLC, a healthcare investment fund, and portfolio manager of Pequot Capital Management’s healthcare fund. Earlier, he worked at the Dreyfus Corporation as a senior managing analyst covering pharmaceuticals, biotechnology, and medical devices.
Alex serves on the Board of Directors of Erasca, Inc., and is Chair of the Audit Committee. Alex has also served on the Boards of Directors for multiple life science companies, including Ignyta Inc. (acquired by Roche) and Dusa Pharmaceuticals, Inc. (acquired by Sun Pharma). He also served as an Investor Board Observer of 454 Life Sciences (acquired by Roche).
Alex is a member on Brown University’s Advisory Council on Biology and Medicine. He is also Treasurer, Executive Committee member, and Board member of The American Society of Clinical Oncology’s Conquer Cancer Foundation. Alex received an M.B.A. from Columbia Business School, Beta Gamma Sigma, and a B.A. in political science from Brown University.